-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Boji Biomedical Technology (Hangzhou) Co.
, Ltd.
recently announced that the US FDA has completed the review of the PD-L1/TGFβ bifunctional fusion protein (product code BJ-005) IND independently developed by the company and has a global patent.
The project can carry out clinical trials in the United States
.
This is after Boji Biomedicine obtained the IND approval of the US FDA for its first tumor-targeting IL-15 fusion protein (BJ-001) in 2019, another independently developed product obtained the US FDA's clinical trial approval
Dr.
Zhang Haizhou
Regarding the approval of the US FDA for BJ-005, Dr.
Haizhou Zhang, co-founder and CEO of Boji Biomedicine, said: "Our second self-developed product was approved for clinical trials in the United States, which once again proved Boji Biomedical The continuous innovation ability and efficient execution power of
the company.
This greatly enhances the company’s confidence in fulfilling the established goal of pushing a completely independent innovation product into clinical research every 1-2 years
Although it has only been in operation for more than 3 years, but adhering to the concept of only making global independent innovative drugs, Boji Biopharmaceuticals has begun to conduct research on tumors and infectious diseases using its biological drug research and development platform protected by trade secrets and its self-developed dual antibody platform.
Layout
.
The BJ-005, which was approved to enter the clinic this time, is one of many innovative products in its R&D pipeline
About Boji Biomedicine
Boji Biomedicine is a biotechnology company in the clinical stage dedicated to the research and development of innovative drugs.
It was founded by returned experts with many years of experience in innovative drug research and development at home and abroad, including review experts for major scientific and technological projects of the country’s “Major New Drug Development” , Possesses an antibody discovery platform protected by trade secrets and advanced technologies at home and abroad.
Currently, it mainly develops biological drugs for tumors and infectious diseases
.
The company's main scientific research and management team has many years of experience in the development and management of macromolecular drugs in national key scientific research institutions and domestic and foreign pharmaceutical companies, especially European and American multinational companies
